Recombinant activated factor VII - A new treatment for obstetric haemorrhage?;Krwotok połozniczy - Nowe mozliwości leczenia?

Anestezjologia Intensywna Terapia

Volumn 35, Issue 2, 2003, Pages 110-112

  Michalska Krzanowska, Grazyna ^a   Stasiak Pikula, Elzbieta ^a   Sajdak, Renata ^a  

^a Reanimacji i IT Pododdzialem Ostrych   (Poland)

Author keywords

Blood, coagulation, recombinant activated factor VII; Complication, cardiac arrest, haemorrhage, thrombosis; Surgery, obstetrics

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; APGAR SCORE; ARTERIAL PRESSURE; ARTICLE; BRAIN DISEASE; CASE REPORT; CESAREAN SECTION; CONVALESCENCE; DELIVERY; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; EDEMA; FEMALE; FETUS HYPOXIA; GENERAL ANESTHESIA; HEART ARREST; HEMOSTASIS; HUMAN; HYSTERECTOMY; INTENSIVE CARE; LABOR INDUCTION; OBSTETRIC HEMORRHAGE; POSTOPERATIVE PERIOD; PREECLAMPSIA; RESPIRATORY TRACT INTUBATION; RESUSCITATION; RISK ASSESSMENT; VEIN THROMBOSIS;

EID: 1842844462     PISSN: 02091712     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bonnar J: Massive obstetric haemorrhage. Clin Obstet Gynaecol 2000; 14: 1-18.
2. Breborowicz GH, Sobieszczyk S: Przydatność rekombinowanego aktywowanego czynnika VIIa (rFVIIa, NovoSeven) w praktyce połozniczej - doświadczenia własne. Klin Perinat Gin 2001; 34: 7-12.
3. Sobieszczyk S, Skrzypczak J, Szymankiewicz M: Zastosowanie rekombinowanego aktywowanego czynnika VII rFVIIa, NovoSeven podczas ciecia cesarskiego u ciezarnej z mechaniczna zastawka serca. Klin Perinat Gin 2001; 34: 173-179.
4. Sajdak S, Moszyński R, Opala T, Perlik M: Kliniczne efekty zastosowania rekombinowanego czynnika krzepniecia VIIa w przypadkach krwawienia u kobiet z nowotworem złośliwym endometrium i pochwy - opis dwóch przypadków. Gin Prakt 2001; 4.
5. Schulman S, d'Oiron R, Martinowitz U: Experiences with continuous infusion of recombinant activated factor VII. Blood Coagul Fibrynolysis 1998; 9 (suppl 1): 91-101.
6. Key NS, Aledort LM, Beardsley D: Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-918.
7. Peerlinck K, Vermylen J: Acute myocardial infarction following administration of recombinant activated factor VII (NovoSeven) in patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82: 1775-1776.
8. Hedner U: Recombinant activated factorVII as a universal haemostatic agent. Blood Coagul Fibrynolysis 1998; 9 (suppl 1): 147-152.
9. Kaliciński P, Kamiński A, Drewniak T: Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transplant Proc 1999; 3: 378-379.
10. Hendrics HGD, Meijer K, de Wolf JTM: Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation. Transplantation 2001; 7: 402-405.
11. Poon M, d'Oiron R and International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group: Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. Blood Coagul. Fibrynolysis 2000; 11, 1: 55-68.
12. Kristensen J, Killander A, Hippe E: Clinical experience with recombinant factor VII in patiens with thrombocytopenia. Haemostasis 1996; 26 (suppl 1): 159-164.
13. Michalska-Krzanowska G, Sajdak R, Stasiak-Pikuła E: Zastosowanie preparatu rekombinowanego czynnika VIIa w leczeniu krwotoku pooperacyjnego w oddziale intensywnej terapii. Opis przypadku. Anest Inten Ter 2002; 34: 24-26.